What is Thymopentin?
Thymopentin is a synthetic pentapeptide studied as an immunomodulator. A small 1985 randomized trial examined active rheumatoid arthritis.
Biological role or research focus
Historical immune-disease research.
The trial was small, short, and historical. It does not establish sustained disease control, prevention of structural joint damage, or benefit across unrelated immune conditions.
Role reference: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
Names you may encounter
TP-5
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Synthetic five-residue immunomodulatory peptide
- Research focus
- Historical immune-disease research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
Quick answers
- Is Thymopentin FDA approved?
- No. No FDA-approved drug contains Thymopentin. Source ↗
- Is Thymopentin safe?
- Not FDA-approved. Small trials from the 1980s reported side effects at rates similar to placebo, but the data are old and limited, so modern safety evidence is thin. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Thymopentin banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Thymopentin rheumatoid-arthritis study (1985) | Human randomized trial | 41 patients with active rheumatoid arthritis; 21 received thymopentin and 20 received placebo. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 1985
Thymopentin rheumatoid-arthritis study
Did clinical and immunological rheumatoid-arthritis measures change?
- Population / model
- 41 patients with active rheumatoid arthritis; 21 received thymopentin and 20 received placebo.
- Study design
- Randomized double-blind placebo-controlled study over three weeks.
- Main finding
- Some joint, pain, and Ritchie-index measures improved between groups. The reported immunological tests did not show corresponding improvements.
- Limits & context
- The trial was small, short, and historical. It does not establish sustained disease control, prevention of structural joint damage, or benefit across unrelated immune conditions.
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
9 registered studies name Thymopentin as an intervention; 0 are recruiting or under way, 0 have not started recruiting yet, 7 completed and 2 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 9 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Copper-coordination driven brain-targeting nanoassembly for efficient glioblastoma multiforme immunotherapy by cuproptosis-mediated tumor immune microenvironment reprogramming. ↗
Journal of nanobiotechnology · 2024 Dec 28 · Journal Article
Read available full text ↗
Thymopentin: safety overview. ↗
Survey of immunologic research · 1985 · Clinical Trial, Journal Article
Thymopentin in dermatology. ↗
Current problems in dermatology · 1989 · Journal Article, Review
Thymopoietin to thymopentin: experimental studies. ↗
Survey of immunologic research · 1985 · Journal Article, Review
Risks & interactions
Not FDA-approved. Small trials from the 1980s reported side effects at rates similar to placebo, but the data are old and limited, so modern safety evidence is thin.
A 1985 overview pooled early trials, some lasting 12 to 24 months in 56 patients, and reported side effects similar to placebo. Trials were small and dated, and a recent dialysis study was retrospective. Long-term immune effects are unclear.
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Thymopentin: safety overview (1985) ↗ · Thymopentin in active rheumatoid arthritis (1985) ↗ · Thymopentin for infection prophylaxis in peritoneal dialysis (2025) ↗
What the featured evidence can tell us
Three weeks of observation in 41 patients cannot resolve long-term immune effects, interactions, or uncommon adverse reactions.
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
Identity, route, and evidence limits
The trial was small, short, and historical. It does not establish sustained disease control, prevention of structural joint damage, or benefit across unrelated immune conditions.
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named. S0 only applies to substances with no government approval anywhere; thymopentin has been reported as approved in some countries outside the US (not verified here), so whether S0 applies is uncertain. Athletes should check with their anti-doping organization. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical context & research status
This historical study does not establish thymopentin as a current standard of rheumatoid-arthritis care, or as general infection prevention.
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
How Thymopentin works
Its research concerns modification of immune responses. The selected trial measured clinical and immunological outcomes, which should be distinguished rather than described as a general “immune boost.”
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
Molecular structure
Questions worth asking
- Is immunomodulation the same as stronger immunity?
- What population, comparator, and route were actually studied?
- The trial was small, short, and historical. It does not establish sustained disease control, prevention of structural joint damage, or benefit across unrelated immune conditions.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is immunomodulation the same as stronger immunity?
No. Immune signaling is context dependent. Improvement in a particular symptom study cannot establish general resistance to infections.
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Confirmative study of the effectiveness of thymopentin in active rheumatoid arthritis. · 1985 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
